Radiotherapy Combined With Immune Checkpoint Inhibitors (ICIs) as Treatment for Locally Advanced Non-small-cell Lung Cancer After Failing Induction Immuno-chemotherapy: a Prospective, Real-world Cohort Study.
Latest Information Update: 19 Sep 2023
At a glance
- Drugs Atezolizumab (Primary) ; Camrelizumab (Primary) ; Cisplatin (Primary) ; Durvalumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary) ; Sintilimab (Primary) ; Sugemalimab (Primary) ; Tislelizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
Most Recent Events
- 13 Sep 2023 New trial record
- 10 Sep 2023 Planned initiation date changed from 29 Aug 2023 to 15 Sep 2023.